Nxera pharma to receive us$15 million from neurocrine biosciences following dosing of first patient in phase 3 trial of nbi-1117568

Tokyo, japan and cambridge, uk, 3 june 202 5 – nxera pharma co., ltd. (“nxera” or “the company”; tse 4565) today announces that its partner, neurocrine biosciences (“neurocrine”) has dosed the first patient in its phase 3 registrational program of nbi-1117568 (nbi-'568) as a potential treatment for schizophrenia, resulting in a payment of us$15 million to nxera (clinical trial id: nct06963034). the us$15 million payment will be fully recognized as revenue in the second quarter of 2025.
NBIX Ratings Summary
NBIX Quant Ranking